• Patent granted in Brazil for RECCE® 327 (R327) and RECCE® 529 (R529) anti-infectives
• Patent covers process for preparation and use of RECCE anti-infectives for treating bacterial and viral infections
• Expands Recce's intellectual property portfolio to Brazil, one of the world's largest antibiotics markets

Recce Pharmaceuticals Limited has announced that the Brazilian National Institute of Industrial Property (INPI) has formally granted a Family 4 patent for the company's RECCE® Anti-Infectives, with an expiry date of 2041. The Brazilian Patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), covering the process for preparation of the RECCE® anti-infectives and their use for the treatment of various diseases, particularly bacterial infections, viral infections, and more. This includes further validating RECCE® anti-infectives from studies in Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Diabetic Foot Infections (DFI), Burn Wounds, Lung Infections (including Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia), Urinary Tract Infections, Gonorrhoea, Influenza, and SARS-CoV-2. The patent also covers administration of the RECCE® anti-infectives by oral, inhalation, transdermal delivery, or by injection. This is Recce's seventh Family 4 patent, alongside patents granted in Australia, Canada, China, Hong Kong, Israel, and Japan, with further Patent Cooperation Treaty (PCT) submissions in respective stages of review or allowance. Recce's intellectual property portfolio is focused on protection in leading antibiotic markets, with Brazil being one of the world's largest and the largest in South America.